Key result
Low lncRNA CASC11 levels are linked to CAD and higher mortality.
Why the study?
To investigate the involvement of long non-coding RNA Cancer Susceptibility 11 in patients with coronary artery disease.
Case-Control (n=164)
LncRNA CASC11 is downregulated in coronary artery disease, inversely correlates with TGF-β1, and its low levels are associated with higher long-term mortality.
Low CASC11 levels associate with higher CAD mortality; hypothesis-generating and should not change practice without prospective validation.
Objective To investigate the involvement of long non-coding RNA (lncRNA) Cancer Susceptibility 11 (CASC11) in patients with coronary artery disease (CAD). Methods This case–control study enrolled patients with CAD and age- and sex-matched healthy control subjects. The plasma levels of lncRNA CASC11 and transforming growth factor-beta 1 (TGF-β1) were measured. Diagnostic values of lncRNA CASC11 and TGF-β1 for CAD were determined using receiver operating characteristic curve analysis. Correlations between plasma levels of lncRNA CASC11 and TGF-β1 were analysed using linear regression. Results The study enrolled 82 patients with CAD and 82 healthy controls. Plasma levels of lncRNA CASC11 were downregulated in patients with CAD, while plasma TGF-β1 levels were upregulated in patients with CAD, compared with healthy controls. Plasma levels of lncRNA CASC11 and TGF-β1 distinguished patients with CAD from healthy controls and were inversely correlated in both groups. LncRNA CASC11 over-expression mediated the downregulation of TGF-β1 in human primary coronary artery endothelial cells, while TGF-β1 over-expression showed no significant effects on lncRNA CASC11 levels. An 8-year follow-up study showed that low lncRNA CASC11 levels were closely correlated with a higher mortality rate in patients with CAD. Conclusion LncRNA CASC11 is downregulated in CAD and inhibits TGF-β1.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted a case-control in Coronary artery disease (n=164). lncRNA CASC11 vs. Healthy controls was evaluated on Plasma levels of lncRNA CASC11 and TGF-β1, and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: